Pulmonary embolism as a part of venous thromboembolic disease has a broad spectrum of clinical presentations from minimal disease to life-threatening right heart failure. Therapy has to be guided by the risk associated with the individual clinical state of the patient. As long as hemodynamics are entirely stable, anticoagulation is given in order to prevent early or late recurrence, thereby allowing for endogeneous thrombolysis and recovery. In hemodynamically instable patients, i.e. patients under cardiopulmonary resuscitation or in shock, there is the need for a rapid reduction of thrombus mass in order to restore right ventricular function. Systemic thrombolysis is the most feasible modality to reduce the thrombus burden of the pulmonary circulation in the short term. For hemodynamically stable patients with right ventricular dysfunction as assessed by echocardiography, there is still some controversy as to whether thrombolysis improves the long-term outcome. At the least, thrombolysis may positively modify the short-term course of acute disease in patients with an extremely low risk of bleeding. When the acute phase has been overcome, secondary prophylaxis with vitamin K antagonists has to be given. The duration of secondary prophylaxis requires an individual assessment of both the risk of recurrence and the risk of bleeding. In the near future, new anticoagulant drugs such as direct thrombin and factor Xa inhibitors will offer new treatment modalities for the acute phase as well as for secondary prophylaxis.

Keywords:
Venous thromboembolism, Thrombolysis, Coagulation
1.
Barritt DW, Jordan SC: Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1960;i:1309–1312.
2.
Basu D, Gallus A, Hirsh J, Cade J: A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287:324–327.
3.
Kearon C: Drug trials that have influenced our practice in the treatment of venous thromboembolism. Thromb Haemost 1997;78:553–557.
4.
Bernardi E, Piccioli A, Oliboni G, Zuin R, Girolami A, Prandoni P: Nomograms for the administration of unfractionated heparin in the initial treatment of acute thromboembolism – an overview. Thromb Haemost 2000;84:22–26.
5.
Kearon C, Harrison L, Crowther M, Ginsberg JS: Optimal dosing of subcutaneous unfractionated heparin for the treatment of deep vein thrombosis. Thromb Res 2000;97:395–403.
6.
Gallus A, Jackaman J, Tillett J, Mills W, Wycherley A: Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986;ii:1293–1296.
7.
Brandjes DP, Heijboer H, Buller HR, de Rijk M, Jagt H, ten Cate JW: Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992;327:1485–1489.
8.
Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med 1997;337:657–662.
9.
Simonneau G, Sors H, Charbonnier B, et al: A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l’Embolie Pulmonaire. N Engl J Med 1997;337:663–669.
10.
van Den Belt AG, Prins MH, Lensing AW, et al: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2000;(2):CD001100.
11.
Huisman MV: Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: A randomized, double-blind, multinational study. J Thromb Haemost 2003;1(suppl 1):OC003.
12.
Eriksson H, Wahlander K, Lundström T, Billing-Clason S, Schulman S, Investigators TI: Extended secondary prevention with the oral direct thrombin inhibitor ximelagatran for 18 months after 6 months of anticoagulation in patients with venous thromboembolism: A randomized, placebo-controlled trial. J Thromb Haemost 2003;1(suppl 1):OC005.
13.
The Matisse Investigators: The MATISSE-PE trial, a multicenter, randomized, open study comparing once-daily fondaparinux (Arixtra®) with adjusted-dose intravenous unfractionated heparin (UFH) in the initial treatment of acute symptomatic pulmonary embolism (PE). J Thromb Haemost 2003;1(suppl 1):OC331.
14.
Hirsh J, Dalen J, Anderson DR, et al: Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119(suppl 1):8S–21S.
15.
Kearon C, Ginsberg JS, Kovacs MJ, et al: Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003;349:631–639.
16.
Crowther MA, Ginsberg JS, Julian J, et al: A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003;349:1133–1138.
17.
Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV: The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332:993–997.
18.
Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS: Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998;279:458–462.
19.
Schulman S, Rhedin AS, Lindmarker P, et al: A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 1995;332:1661–1665.
20.
Schulman S: Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003;349:675–683.
21.
Hull R, Hirsh J, Jay R, et al: Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982;307:1676–1681.
22.
Beyth RJ, Quinn LM, Landefeld S: Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998;105:91–99.
23.
Kuijer PM, Hutten BA, Prins MH, Buller HR: Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999;159:457–460.
24.
Schulman S, Granqvist S, Holmstrom M, et al: The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 1997;336:393–398.
25.
Kearon C, Gent M, Hirsh J, et al: A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340:901–907.
26.
Agnelli G, Prandoni P, Santamaria MG, et al: Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 2001;345:165–169.
27.
Ridker PM, Goldhaber SZ, Danielson E, et al: Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425–1434.
28.
Seligsohn U, Lubetsky A: Genetic susceptibility to venous thrombosis. N Engl J Med 2001;344:1222–1231.
29.
Baglin T, Luddington R, Brown K, Baglin C: Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: Prospective cohort study. Lancet 2003;362:523–526.
30.
van der Heijden JF, Hutten BA, Büller HR, Prins MH: Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev 2002;(1):CD002001.
31.
Agnelli G, Prandoni P, Becattini C, et al: Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003;139:19–25.
32.
Koopman MM, Buller HR: Short- and long-acting synthetic pentasaccharides. J Intern Med 2003;254:335–342.
33.
Dalen JE, Alpert JS, Hirsch J: Thrombolytic therapy for pulmonary embolism: Is it effective? Is it safe? When is it indicated? Arch Intern Med 1997;157:2550–2556.
34.
Kasper W, Konstantinides S, Geibel A, et al: Management strategies and determinants of outcome in acute major pulmonary embolism: Results of a multicenter registry. J Am Coll Cardiol 1997;30:1165–1171.
35.
Arcasoy SM, Vachani A: Local and systemic thrombolytic therapy for acute venous thromboembolism. Clin Chest Med 2003;24:73–91.
36.
Wood KE: Major pulmonary embolism: Review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest 2002;121:877–905.
37.
Kasper W, Konstantinides S, Geibel A, Tiede N, Krause T, Just H: Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart 1997;77:346–349.
38.
Kasper W, Geibel A, Tiede N, et al: Distinguishing between acute and subacute massive pulmonary embolism by conventional and Doppler echocardiography. Br Heart J 1993;70:352–356.
39.
Goldhaber SZ, Visani L, De Rosa M: Acute pulmonary embolism: Clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999;353:1386–1389.
40.
Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W, the Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators: Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002;347:1143–1150.
41.
Reekers JA, Baarslag HJ, Koolen MG, Van Delden O, Van Beek EJ: Mechanical thrombectomy for early treatment of massive pulmonary embolism. Cardiovasc Intervent Radiol 2003;26:246–250.
42.
Muller-Hulsbeck S, Brossmann J, Jahnke T, et al: Mechanical thrombectomy of major and massive pulmonary embolism with use of the Amplatz thrombectomy device. Invest Radiol 2001;36:317–322.
43.
Fava M, Loyola S, Huete I: Massive pulmonary embolism: Treatment with the hydrolyser thrombectomy catheter. J Vasc Interv Radiol 2000;11:1159–1164.
44.
Schmitz-Rode T, Janssens U, Duda SH, Erley CM, Gunther RW: Massive pulmonary embolism: Percutaneous emergency treatment by pigtail rotation catheter. J Am Coll Cardiol 2000;36:375–380.
45.
Murphy JM, Mulvihill N, Mulcahy D, Foley B, Smiddy P, Molloy MP: Percutaneous catheter and guidewire fragmentation with local administration of recombinant tissue plasminogen activator as a treatment for massive pulmonary embolism. Eur Radiol 1999;9:959–964.
46.
Gulba DC, Schmid C, Borst HG, Lichtlen P, Dietz R, Luft FC: Medical compared with surgical treatment for massive pulmonary embolism. Lancet 1994;343:576–577.
47.
Beer JH, Burger M, Gretener S, Bernard-Bagattini S, Bounameaux H: Outpatient treatment of pulmonary embolism is feasible and safe in a substantial proportion of patients. J Thromb Haemost 2003;1:186–187.
© 2003 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.